secwatch.observer — SEC 8-K summary
======================================

Issuer:     REATA PHARMACEUTICALS INC (—)
CIK:        0001358762
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-242619
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reata acquired by Biogen; shareholders receive $172.50/share cash
-----------------------------------------------------------------

- Merger closed Sept 26, 2023; Reata now wholly-owned subsidiary of Biogen.
- Each share of Reata common stock converted into $172.50 cash per share.
- Reata requested delisting from Nasdaq and deregistration with SEC.
- All Reata directors resigned; new directors appointed by Biogen.
- Biogen prepaid outstanding term loans under Loan Agreement upon change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1358762/000119312523242619/0001193125-23-242619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1358762/000119312523242619/d516210d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-242619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer